Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy

Authors

DOI:

https://doi.org/10.18370/2309-4117.2026.82.6-18

Keywords:

International Forum of Experts on Menopausal Hormone Therapy, resolution, menopausal hormone therapy, estrogens, dydrogesterone

Abstract

The VII International Forum of Experts on Menopausal Hormone Therapy (MHT) was held in Kyiv on November 18, 2025. The modern approach to the MHT prescription is not to resolve the issue of its appropriateness, but to choose the optimal form for a particular woman. Different routes of hormone administration have different pharmacokinetic properties and effects on metabolism, the coagulation system, and women’s somatic health. The recommendations of the European Menopause and Andropause Society emphasize the appropriateness of using combined MHT to improve the glycemic profile and delay the development of diabetes mellitus, with a preference for metabolically neutral progestogens – progesterone and dydrogesterone.
Transdermal estrogens enter the systemic circulation directly, minimizing the effect on the liver and coagulation, which makes them the method of choice for women with an increased risk of venous thrombosis, obesity, or hypertriglyceridemia. At the same time, the effectiveness of transdermal MHT is characterized by significant interindividual variability.
MHT is an effective antiresorptive method for the prevention of osteoporosis and fractures. Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone. Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases. The individual choice of the form of MHT is a key factor in its safety and clinical efficacy.
Particular attention should be paid to oncological safety, particularly the risk of breast cancer, when selecting MHT in patients using a levonorgestrel-releasing intrauterine system. Data from systematic reviews and meta-analyses indicate that the use of estrogens does not increase this risk, while it largely depends on the type of progestogen. Progesterone and dydrogesterone have the most favorable safety profile for the breast compared with synthetic gestagens, which is confirmed by the results of large-scale studies.
Psychoemotional and sexual disorders (anxiety, depression, sleep disorders, and decreased libido) are common in perimenopause and are largely due to systemic estrogen deficiency, which affects neurometabolic, vascular, and neuroendocrine homeostasis. The high frequency of these disorders justifies the need for comprehensive diagnostic assessment and individualized MHT in perimenopausal women.

Author Biographies

T.F. Tatarchuk, SI “Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine”; National Medical University “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

DSc, professor, corresponding member of the NAMS of Ukraine, deputy general director, head of the Department of Endocrine Gynecology
chief research fellow, Department of Reproductive Health

N.Y. Pedachenko, Shupyk National University of Healthcare of Ukraine, Kyiv

DSc, professor, head of the Department of Obstetrics and Gynecology

G.O. Grebennikova, Kazakhstan Association of Sexual and Reproductive Health, Almaty

PhD, obstetrician-gynecologist, UNFPA expert, Executive Director

O.L. Gromova, O.O. Bogomolets National Medical University, Kyiv

DSc, associate professor, Department of Hospital Obstetrics and Gynecology of Postgraduate Education

D.T. Kayumova, Tashkent State Medical University, Tashkent

DSc, associate professor, Department of Obstetrics and Gynecology

O.G. Yashina, Medikom Clinic, Kyiv

PhD, leading specialist

L.R. Agababyan, Samarkand State Medical University, Samarkand

professor, head of the Department of Obstetrics and Gynecology with a Neonatology Course

L.M. Begimbekova, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent

PhD, associate professor, obstetrician-gynecologist, head of the Department of Obstetrics, Gynecology and Pediatrics

F.A. Gafurova, Center for the Development of Professional Qualifications of Medical Workers, Tashkent

DSc, associate professor, head of the Department of Obstetrics, Gynecology and Perinatal Medicine No. 1

M.A. Gegechkori, Zurab Sabahtarashvili Reproductive Clinic, Tbilisi

DSc, reproductive medicine specialist

A.P. Dzhaimbetova, Kazakhstan Association of Sexual and Reproductive Health; UNFPA, Almaty

obstetrician-gynecologist, Expert
expert

T.O. Yermolenko, Odessa National Medical University, Odessa

DSc, professor, Department of Obstetrics and Gynecology

O.O. Yefimenko, SI “Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine”, Kyiv

DSc, leading research fellow

G.Z. Yeshimbetova, Center for the Development of Professional Qualifications of Medical Workers, Tashkent

DSc, professor, Department of Obstetrics, Gynecology and Perinatal Medicine No. 1

N.F. Zakharenko, State National University “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

DSc, professor, chief research fellow, Department of Reproductive Health

S.U. Irgasheva, Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health, Tashkent

DSc, professor

I.L. Kopobayeva, National Academy of Sciences «Karaganda Medical University»; Karaganda Branch of the KMPA, Karaganda

assistant professor, Department of Obstetrics, Gynecology and Perinatology
President

N.V. Kosei, National Medical University «Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

DSc, professor, head of the Department of Reproductive Health

D.I. Kristesashvili, Center for Reproductive Medicine «Universi», Tbilisi

DSc, professor, deputy director

P.N. Mikailzade, Clinic «German», Baku

obstetrician-gynecologist

G.T. Myrzabekova, Center for Molecular Medicine, Almaty

obstetrician-gynecologist

R.O. Mnevets, SI “Ukrainian Center of Maternity and Childhood of the NAMS of Ukraine”; National Center “Institute of Biology and Medicine” of the Taras Shevchenko National University of Kyiv, Kyiv

postgraduate student, Department of Endocrine Gynecology
assistant professor, Department of Pediatrics, Obstetrics and Gynecology

S.D. Muratova, Mirad Garriyev Turkmen State Medical University, Ashgabat

PhD, assistant professor, Department of Obstetrics and Gynecology

I.G. Persoyan, Beglaryan Medical Center; Armenian Anti-Aging Medical Association, Yerevan

PhD, head of the Women’s Consultation
president

V.I. Pyrogova, Lviv National Medical University named after Danylo Halytsky, Lviv

DSc, professor, Department of Obstetrics, Gynecology and Reproductive Medicine

N.M. Rozhkovska, Odessa National Medical University, Odessa

DSc, рrofessor, Department of Obstetrics and Gynecology

L.V. Stavinska, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau

PhD, associate professor, Department of Obstetrics and Gynecology

T.M. Ukybasova, National Scientific Center for Motherhood and Childhood, Corporate fund “University Medical Center», Astana

DSc, professor, obstetrician-gynecologist

References

  1. Melton LJ, 3rd, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998 Dec;13(12):1915–23. DOI 10.1359/jbmr.1998.13.12.1915
  2. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture в Malmo. Osteoporos Int. 2000;11(8):669-74. DOI 10.1007/s001980070064.
  3. de Villiers. Bone health and menopause: Osteoporosis prevention and treatment. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101782. DOI 10.1016/j.beem.2023.101782.
  4. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049–102. DOI 10.1007/s00198-021-05900-y.
  5. De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, et al. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad. American College of Sports Medicine. Br J Sports Med. 2014 Feb;48(4):289. DOI 10.1136/bjsports-2013-093218.
  6. Viljakainen HT. Factors influencing bone mass accrual: focus on nutritional aspects. Proceedings of the Nutrition Society. 2016;75(3):415-419. DOI10.1017/S0029665116000252.
  7. Kontele I, Vassilakou T. Nutritional Risks among Adolescent Athletes with Disordered Eating. Children. 2021 Aug 21;8(8):715. DOI 10.3390/children8080715.
  8. Ferreira LB, Tirapeli KG, Silva CC, Goldberg TBL. Lumbar spine bone mineral density in women Breastfeeding for period to 4 to 6 months: systematic review and meta-analysis. Int Breastfeed J. 2023 Dec 18;18(1):68. DOI 10.1186/s13006-023-00607-8.
  9. Shieh A, Karlamangla AS, Karvonen-Guttierez CA, Greendale GA. Menopause-Related Changes in Body Composition Are Associated with Subsequent Bone Mineral Density and Fractures: Study of Women’s Health Across the Nation. J Bone Miner Res. 2023 Mar;38(3):395-402. DOI 10.1002/jbmr.4759. Epub 2023 Jan 17.
  10. Shieh A, Ruppert KM, Greendale GA, et al. Associations of Age at Menopause З Postmenopausal Bone Mineral Density and Fracture Risk in Women. J Clin Endocrinol Metab. 2022 Jan 18;107(2):e561-e569. DOI 10.1210/clinem/dgab690.
  11. Ng JS, Chin KY. Potential mechanisms linking psychological stress to bone health. International Journal of Medical Sciences. 2021. 18(3):604-614. DOI 10.7150/ijms.50680
  12. Klimova ZhA, Zaft AA, Zaft VB. Modern laboratory diagnostics of osteoporosis. International Endocrinological Journal. 2014;7(63).
  13. The ESHRE Guideline Group on POI. ESHRE Guideline on the management of women with Premature Ovarian Insufficiency [Internet]. ESHRE, 2024. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/POI/2024/POI-GUIDELINE_Patient-version_2024dec.pdf
  14. Zhang S, Huang X, Zhao X, Li B, Cai Y, Liang X, et al. Effect of exercise on bone mineral density among patients with osteoporosis and osteopenia: A systematic review and network meta-analysis. J Clin Nurs. 2022 Aug;31(15-16):2100-2111. DOI 10.1111/jocn.16101.
  15. Order of the Ministry of Health of Ukraine No. 1039 of June 17, 2022. “Clinical guidance and Unified clinical protocol for primary, secondary (specialized), tertiary (highly specialized) medical care “Menopausal disorders and other disorders in the perimenopausal period”. [Internet]. Ministry of Health of Ukraine, 2022. Available from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-17062022--1039-pro-zatverdzhennja-unifikovanogo-klinichnogo-protokolu-pervinnoi-vtorinnoi-specializovanoi-tretinnoi-visokos-pecializovanoi-medichnoi
  16. Cummings SR, Bates D, Black DM. Clinical Use of Bone Densitometry: Scientific Review. JAMA. 2002;288;(15):1889-1897. DOI10.1001/jama.288.15.1889.
  17. Network International Society for Clinical Densitometry. 2019 Adult Official Positions. [Internet]. ISCD, 2019. Available from: https://iscd.org/wp-content/uploads/2021/09/2019-Official-Positions-Adult-1.pdf
  18. Liu Y, Le S, Liu Y, Jiang H, Ruan B, Huang Y, et al. The effect of calcium supplementation in people under 35 years old: A systematic review and meta-analysis of randomized controlled trials. Elife. 2022 Sep 27;11:e79002. DOI 10.7554/eLife.79002.
  19. Dong SL, Jiao Y, Yang HL. Effectiveness of bisphosphonates on bone mineral density in osteopenic postmenopausal women: A systematic review and network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021 Aug 6;100(31):e26715. DOI 10.1097/MD.0000000000026715.
  20. Mochizuki T, Yano K, Ikari K, Okazaki K. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia. 2021 Sep;7(3): 110-114. DOI 10.1016/j.afos.2021.08.001.
  21. Jiang L, Dong J, Wei J, Liu L. Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2022 Nov 29;23(1):1027. DOI 10.1186/s12891-022-05997-0.
  22. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74. DOI 10.1007/s12325-021-01936-y.
  23. Nargesi S, Barghazan SH, Sani’ee N, Kemmak AR. Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review. Iran J Public Health. 2022 Jul;51(7): 1502-1512. DOI 10.18502/ijph.v51i7.10084.
  24. Stevenson J, Teter P, Lees B. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas. 2001;38:197-203. DOI: 10.1016/s0378-5122(00)00219-x.
  25. Vinogradova Y, Iyen B, Masud T, Taylor L, Kai J. Discontinuation of menopausal hormone therapy and risk of fracture: nested case-control studies using routinely collected primary care data. Lancet Healthy Longev. 2025 Jul;6(7):100729. DOI 10.1016/j.lanhl.2025.100729.
  26. Stevenson TEJ, Brincat MP, Pollacco J, Stevenson JC. Effect of hormone replacement therapy on intervertebral disc height. Climacteric. 2023; 26 (2): 110-113. DOI10.1080/13697137.2022.2158728
  27. Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources. [Internet]. Endocrine Society. 2020 Feb 18. Available from: https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women.
  28. Pagnotti GM, Styner M, Uzer G, Patel VS, Wright LE, Ness KK, et al. Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. Nat Rev Endocrinol. 2019 Jun;15(6):339-355 DOI 10.1038/s41574-019-0170-1
  29. Lee DO, Hong YH, Cho MK, Choi YS, Chun S, Chung YJ, et al. 2024 Guidelines for Osteoporosis – Korean Society of Menopause: Part II. J Menopausal Med. 2024 Aug; 30 (2): 55-77. DOI 10.6118/jmm.300001
  30. Edwards I. HealthDay News. FDA weighs warning label change for menopause hormone therapy. [Internet]. 2025. Available from: https://www.upi.com/Health_News/2025/10/06/FDA-warning-label-hormone-replacement-menopause/8001759762765/.
  31. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. [Internet]. FDA, November 10, 2025. Available from: https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
  32. Duncan AC, Lyall H, Roberts RN, Petrie JR, Perera MJ, Monaghan S, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women, J. Clin. Endocrinol. Metab. 1999;84:2402–7. DOI 10.1210/jcem.84.7.5836
  33. Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, et al. Menopause and diabetes: EMAS clinical guide. Maturitas 117 (2018) 6–10. DOI 10.1016/j.maturitas.2018.08.009.
  34. Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–88. DOI 10.1016/j.maturitas.2020.03.007.
  35. Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group Maturitas. 2022; 166:65-85. DOI10.1016/j.maturitas.2022.08.008.
  36. Panay N, Ang SB, Cheshire R, Goldstein SR, Maki P, Nappi RE; International Menopause Society Board. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. Climacteric. 2024 Oct;27(5):441-457. DOI 10.1080/13697137.2024.2394950.DOI
  37. MHT Eligibility Criteria Group. Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases. Maturitas. 2025 Apr:195:108208. DOI 10.1016/j.maturitas.2025.108208
  38. Linton A, Golobof A, Shulman LP. Contraception for the perimenopausal woman. Climacteric. 2016 Dec;19(6):526-534. DOI 10.1080/13697137.2016.1225033.
  39. WHO. Medical eligibility criteria for contraceptive use. Fifth edition [Internet]. WHO, 2015. Available from: https://www.afro.who.int/sites/default/files/2017-06/WHO_ RHR_15.07_eng.pdf
  40. Chen WY. Factors that modify breast cancer risk in women. [Internet]. UpToDate 2020. Available from: https://www.uptodate.com/contents/factors-that-affect-breast-cancer-risk-in-women-beyond-the-basics
  41. Huck LC, Truhn D, Wilpert C, Zanderigo E, Raaff V, Dethlefsen E, et al. Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices. Eur Radiol. 2022 May 7. DOI 10.1007/s00330-022-08809-0
  42. Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017 Feb;33(2):87-92. DOI 10.1080/09513590.2016.1248932
  43. Gompel A, Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment. Climacteric. 2018 Aug;21(4):326-332. DOI 10.1080/13697137.2018.1476483
  44. Franke НR, Vermes I. Di erential e ects of progestogens оn breast cancer cell. lines. Maturitas. 2003; 46 Suppl 1:S55–S58. DOI 10.1016/j.maturitas.2003.09.019.
  45. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat . 2008 Jan;107(1):103-11. DOI 10.1007/s10549-007-9523-x.
  46. Collaborative Group оп Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 28;394(10204):1159-1168. DOI 10.1016/S0140-6736(19)31709-X. Epub 2019 Aug 29.
  47. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020 Oct 28:371:m3873. DOI 10.1136/bmj.m3873.
  48. Yuk JS. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study. Int J Gynaecol Obstet. 2024;166(2):735-744. DOI10.1002/ijgo.15461
  49. Panay N, Fenton A, Hamoda H, Hillard T, Islam R, Pedder H, et al. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025; 28(6): 634–656. DOI 10.1080/13697137.2025.2585487
  50. Resolution of the II International Forum of Experts on Menopausal Hormone Therapy, Reproductive Endocrinology. 2021;4(60):77–84. DOI 10.18370/2309 4117.2021.60.77 84.
  51. British Menopause Society. Management of unscheduled bleeding on hormone replacement therapy (HRT). [Internet]. BMS, 2024. Available from: https://nhssomerset.nhs.uk/wp-content/uploads/sites/2/01-BMS-GUIDELINE-Management-of-unscheduled-bleeding-HRT-MAY2024-G.pdf
  52. American Cancer Society. Endometrial Cancer Risk Factors. [Internet]. American Cancer Society, 2025. Available from: https://www. cancer.org/content/dam/CRC/PDF/Public/8610.00.pdf
  53. National Cancer Institute. Endometrial Cancer Prevention (PDQ®) – Health Professional Version. [Internet]. SpringWorks Therapeutics, 2025. Available from: https://www.cancer. gov/types/uterine/hp/endometrial-prevention-pdq
  54. Eyster KM. The Estrogen Receptors: An Overview from Different Perspectives. Methods Mol Biol. 2016:1366:1-10. DOI 10.1007/978-1-4939-3127-9_1
  55. Kayumova D.T. Sexual disorders in women depending on age. Global Science Research Journals 2019;7(3):262-266. DOI: https://doi.org/10.61841/f4qt6256.
  56. Economic Impact of Menopause: Individual and Collective Costs. AARP Survey of U.S. Women Ages 35-Plus and U.S. Employers. By Jennifer Sauer et al. [Internet]. ICMGLT, Published November 10, 2023/ Updated April 25, 2024. Available from: https://www.aarp.org/pri/topics/work-finances-retirement/employers-workforce/menopause-workplace.html
  57. Chang CY, Tsai FJ, Chiou JS, et al. Timing and dosage of and adherence to hormone replacement therapy and fracture risk in women with menopausal syndrome in Taiwan: A nested case-control study. Maturitas. 2021 Apr;146:1-8. DOI 10.1016/j.maturitas.2020.12.010.
  58. Korniiets NG, Tertychna-Teliuk SV, Hryshyna OS, Kulyk SV, Krasnopolska YV, Priadko RM. Studying the awareness level and attitude of Ukrainian women towards menopausal hormone therapy. Results of a sociological survey. Reproductive health of woman. 2025 Sep 6 (85): 34-44. DOI10.30841/2708-8731.6.2025.341003
  59. Bunnewell S, Keating S, Parsons J, Hickey M, Hillman S. Women’s and Health Care Professionals’ Experiences of Discontinuing Hormone Replacement Therapy (HRT): A Systematic Review. BJOG. 2025 Sep 26. DOI 10.1111/1471-0528.70023.

Downloads

Published

2026-04-18

How to Cite

Tatarchuk, T., Pedachenko, N., Grebennikova, G., Gromova, O., Kayumova, D., Yashina, O., Agababyan, L., Begimbekova, L., Gafurova, F., Gegechkori, M., Dzhaimbetova, A., Yermolenko, T., Yefimenko, O., Yeshimbetova, G., Zakharenko, N., Irgasheva, S., Kopobayeva, I., Kosei, N., Kristesashvili, D., Mikailzade, P., Myrzabekova, G., Mnevets, R., Muratova, S., Persoyan, I., Pyrogova, V., Rozhkovska, N., Stavinska, L., & Ukybasova, T. (2026). Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy. REPRODUCTIVE ENDOCRINOLOGY, (82), 6–18. https://doi.org/10.18370/2309-4117.2026.82.6-18

Issue

No. 82 (2026)

Section

Management of menopause

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.